BH3 mimetics selectively eliminate chemotherapy-induced senescent cells and improve response in TP53 wild-type breast cancer

• Published in: Cell death and differentiation Vol. 27; no. 11; pp. 3097 - 3116
• Main Authors: Shahbandi, Ashkan, Rao, Sonia G., Anderson, Ashlyn Y., Frey, Wesley D., Olayiwola, Joy O., Ungerleider, Nathan A., Jackson, James G.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.11.2020; Nature Publishing Group
• Subjects: 13; 14; 14/63; 631/208/68; 631/67/70; 631/80; 64; 64/60; 82; 82/1; Apoptosis; Bcl-x protein; Biochemistry; Biomedical and Life Sciences; Breast cancer; Cancer therapies; Cell Biology; Cell Cycle Analysis; Cell proliferation; Chemokines; Chemotherapy; Cytokines; Genome editing; Life Sciences; Mcl-1 protein; Medical prognosis; Metastases; p53 Protein; Phenotypes; Senescence; Stem Cells; Tumor cells; Tumors
• DOI: 10.1038/s41418-020-0564-6
• ISSN: 1350-9047

TP53 wild-type breast tumors rarely undergo a complete pathological response after chemotherapy treatment. These patients have an extremely poor survival rate and studies show these tumors preferentially undergo senescence instead of apoptosis. These senescent cells persist after chemotherapy and secrete cytokines and chemokines comprising the senescence associated secretory phenotype, which promotes survival, proliferation, and metastasis. We hypothesized that eliminating senescent tumor cells would improve chemotherapy response and extend survival. Previous studies have shown “senolytic” agents selectively kill senescent normal cells, but their efficacy in killing chemotherapy-induced senescent cancer cells is unknown. We show that ABT-263, a BH3 mimetic that targets antiapoptotic proteins BCL2/BCL-XL/BCL-W, had no effect on proliferating cells, but rapidly and selectively induced apoptosis in a subset of chemotherapy-treated cancer cells, though sensitivity required days to develop. Low NOXA expression conferred resistance to ABT-263 in some cells, necessitating additional MCL1 inhibition. Gene editing confirmed breast cancer cells relied on BCL-XL or BCL-XL/MCL1 for survival in senescence. In a mouse model of breast cancer, ABT-263 treatment following chemotherapy led to apoptosis, greater tumor regression, and longer survival. Our results reveal cancer cells that have survived chemotherapy by entering senescence can be eliminated using BH3 mimetic drugs that target BCL-XL or BCL-XL/MCL1. These drugs could help minimize residual disease and extend survival in breast cancer patients that otherwise have a poor prognosis and are most in need of improved therapies.